3/19
07:39 am
sonn
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting [Yahoo! Finance]
3/19
07:30 am
sonn
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Medium
Report
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
3/11
07:41 am
sonn
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective [Yahoo! Finance]
High
Report
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective [Yahoo! Finance]
3/11
07:30 am
sonn
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Medium
Report
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
2/29
04:26 pm
sonn
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers [Yahoo! Finance]
2/29
04:05 pm
sonn
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Medium
Report
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
2/17
09:19 am
sonn
Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
2/15
01:20 pm
sonn
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $75.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $75.00 to $30.00. They now have a "buy" rating on the stock.
2/14
07:37 am
sonn
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update [Yahoo! Finance]
2/14
07:30 am
sonn
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Medium
Report
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update